Granata Bio and Amphastar Pharmaceuticals enter into an agreement for the commercialization of Ganirelix Acetate Injection
Granata Bio, Inc. has announced it has entered into an agreement with Amphastar Pharmaceuticals, Inc. for the commercialization of Ganirelix Acetate Injection, 250 mcg/0.5mL in a prefilled syringe.
Under the terms of the agreement, Granata Bio, Inc., a biotech company focused on infertility, will promote Ganirelix Acetate to its established network of fertility-focused customers.
"Competition is essential to ensure patients get high quality products at competitive prices. Granata Bio is excited to collaborate with the Amphastar team on Ganirelix Acetate Injection. We look forward to this new partnership which will allow us to provide patients with cost-effective options for their IVF treatment,” said Evan Sussman, Co-founder and CEO of Granata Bio, Inc.
About Ganirelix Acetate Injection
Ganirelix Acetate Injection, 250 mcg/0.5mL in a prefilled syringe. Ganirelix acetate injection is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation. Amphastar’s Ganirelix Acetate Injection was approved in April 2022 as a bioequivalent and therapeutically equivalent to Organon Pharmaceuticals’ Ganirelix Acetate Injection.
About Amphastar Pharmaceuticals
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.
More information and resources are available at www.amphastar.com.
About Granata Bio
Granata Bio is a US-based biopharma company focused on women's health and infertility. Founded in 2018, Granata’s pipeline includes collaborations spanning four different IVF product classes.